NIAID Biodefense Pathogens

NIAID’s biodefense pathogen list is periodically reviewed and is subject to revision in conjunction with our federal partners, including the U.S. Department of Homeland Security, which determines threat assessments, and the Centers for Disease Control and Prevention, which is responsible for responding to emerging pathogen threats in the United States.

Research on microbial- or plant-derived toxins or antimicrobial resistance may also be included.

Bacteria

  • Bacillus anthracis (anthrax)
  • Bordetella pertussis (new in  FY15)
  • Borrelia mayonii (new in FY18)
  • Borrelia miyamotoi (new in FY14)
  • Brucella species (brucellosis)
  • Burkholderia mallei (glanders)
  • Burkholderia pseudomallei (melioidosis)
  • Campylobacter jejuni3
  • Chlamydia psittaci (psittacosis)
  • Coxiella burnetii (Q fever)
  • Ehrlichia
  • diarrheagenic Escherichia coli3
  • Francisella tularensis (tularemia)
  • Leptospira (new in FY14)
  • Listeria monocytogenes3
  • Rickettsia prowazekii (typhus fever) and other Rickettsias
  • Salmonella3
  • Shigella3
  • Tuberculosis
  • pathogenic Vibrios3
  • Yersinia enterocolitica3
  • Yersinia pestis (plague)

Fungi

  • Coccidioides
  • Microsporidia3
  • Mucorales (new in FY14)

Protozoa

  • Balamuthia mandrillaris3 (new in FY14)
  • Cryptosporidium parvum3
  • Cyclospora cayetanensis3
  • Entamoeba histolytica3
  • Giardia lamblia3
  • Naegleria fowleri3 (new in FY14)
  • Toxoplasma gondii3 

Viruses

Toxins/Other Infectious Agents

  • Botulinum toxin/Botulism (Clostridium botulinum)
  • Epsilon toxin (Clostridium perfringens)
  • Prions
  • Ricin toxin (Ricinus communis)
  • Staphylococcal enterotoxin B (SEB)

Antimicrobial Resistance

  • Serious and urgent threats as identified by the CDC 2019 AR Threat report 
  • Studies on resistance mechanisms, intervention development targeting antimicrobial-resistant pathogens, broad-spectrum antimicrobials, antibiotic stewardship, unexpected antibiotic failure, and (reduction/circumvention of) resistance emergence

Immunologic Studies

Immunology studies that advance our understanding of host defenses are critical for the development of vaccines, therapeutics, and diagnostics.  While our knowledge of immune system regulation and function is increasing, there is still much to be learned regarding the mechanisms required to provide protection against infectious disease.  Therefore, areas advancing NIAID’s biodefense effort include, but are not limited to, the following in the context of infectious disease and relevant model antigens:

  • Vaccine adjuvant discovery, mechanisms of action and development
  • Immune epitope (antibody / B cell / T cell) discovery, immunopathogenesis, and/or mechanisms of protection
  • Immunotherapeutics/host-directed therapies, antibody-based therapeutics
  • Mechanisms regulating the induction and durability of B and T cell memory
  • Mechanisms of inflammation and tissue damage triggered by immune dysfunction
  • Mechanisms of immune cell killing/clearance of infected cells
  • Functions of innate immune cells, receptors, or soluble mediators
  • Mucosal immunology
  • Skin immunology

Notes

  1. This list was created for the purpose of extramural and intramural program management within the NIAID biodefense/emerging infectious disease mission and does not represent the complete scope of biodefense and emerging infectious disease.
  2. Pathogens listed on this page are not all select agents regulated by the U.S. Federal Select Agent Program (FSAP).  For a list of select agents regulated by the U.S. FSAP, refer to the Select Agents and Toxins List.
  3. Food- and/or waterborne pathogen
  4. Mosquito-borne viruses
  5. Tickborne encephalitis complex flaviviruses
  6. Tickborne hemorrhagic fever bunyaviruses
  7. Tickborne hemorrhagic fever flaviviruses
  8. Viral hemorrhagic fevers (arenaviruses)
  9. Viral hemorrhagic fevers (bunyaviruses)
  10. Viral hemorrhagic fevers (flaviviruses)
  11. Viral hemorrhagic fevers (filoviruses)
Content last reviewed on